Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MOGAT2 | Q3SYC2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3885828 | 1.00 | CNR2 (0.57) | CNR2ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL10080089 | 1.00 | CNR2 (0.57) | CNR2ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL7955002 | 0.84 | CA12 (0.57) | ALDH1A1KDM4EHPGDHSD17B10POLB | |
| SCHEMBL6333241 | 0.81 | ALDH1A1 (0.51) | CNR2ALDH1A1POLBCA12CA7 | |
| SCHEMBL1938001 | 0.81 | ALDH1A1 (0.51) | ALDH1A1KDM4EHPGDHSD17B10POLB | |
| SCHEMBL5682335 | 0.81 | ALDH1A1 (0.51) | ALDH1A1KDM4EHPGDHSD17B10POLB | |
| SCHEMBL7568229 | 0.81 | ALDH1A1 (0.51) | ALDH1A1KDM4EHPGDHSD17B10POLB | |
| SCHEMBL9184442 | 0.81 | ALDH1A1 (0.51) | CNR2ALDH1A1POLBCA12CA7 | |
| SCHEMBL10312259 | 0.81 | CNR2 (0.51) | CNR2ALDH1A1 | |
| SCHEMBL5682340 | 0.81 | ALDH1A1 (0.51) | ALDH1A1KDM4EHPGDHSD17B10POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230478-A1 | 4-Alkyl-substituted diaminopyrimidines | Bayer ScienceCrop AG (DE) | 2011-09-22 | — | — | US | claimed |
| EP-2330904-A2 | 4-ALKYL-SUBSTITUTED DIAMINOPYRIMIDINES | Bayer CropScience AG (DE) | 2011-06-15 | — | — | EP | claimed |
| WO-2010025863-A2 | 4-ALKYL-SUBSTITUTED DIAMINOPYRIMIDINES | BAYER CROPSCIENCE AG (DE) | 2010-03-11 | — | — | WO | claimed |
| WO-2024164666-A1 | METHOD FOR PREPARING BENZYLAMINE DERIVATIVE BY VISIBLE LIGHT-PROMOTED NICKEL-CATALYZED AMINATION OF BENZYL C-H BONDS | 上海沃凯生物技术有限公司 | 2024-08-15 | — | — | WO | disclosed |
| CN-116063209-B | Method for preparing benzylamine derivative by catalyzing amination of benzyl C-H bond through nickel under promotion of visible light | 上海沃凯生物技术有限公司 | 2024-04-09 | — | — | CN | disclosed |
| EP-3838903-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2023-11-22 | — | — | EP | disclosed |
| CN-116063209-A | Method for preparing benzylamine derivative by catalyzing amination of benzyl C-H bond through nickel under promotion of visible light | 上海沃凯生物技术有限公司 | 2023-05-05 | — | — | CN | disclosed |
| US-11524961-B2 | JAK kinase inhibitor and preparation method and use thereof | SHANGHAI LONGWOOD BIOPHARMACEUTICALS CO., LTD. (CN) | 2022-12-13 | — | — | US | disclosed |
| EP-3838903-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR | Incyte Holdings Corporation (US) | 2021-06-23 | — | — | EP | disclosed |
| CN-108976178-B | Preparation method of chiral sulfonamide organic compound | 云南民族大学 | 2020-06-05 | — | — | CN | disclosed |
| EP-3466953-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR | Incyte Holdings Corporation (US) | 2019-04-10 | — | — | EP | disclosed |
| US-20090099143-A1 | TETRAHYDRO-INDAZOLE CANNABINOID MODULATORS | LAGU BHARAT | 2009-04-16 | — | — | US | disclosed |
| CN-101386590-A | Pyrrolidone containing hydroxymethyl and carboxyl, preparation method and medicament composition and use thereof | INST MATERIA MEDICA CAMS (CN) | 2009-03-18 | — | — | CN | disclosed |
| US-7452997-B2 | Tetrahydro-indazole cannabinoid modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-11-18 | — | — | US | disclosed |
| US-20080176911-A1 | ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS | SANOFI-AVENTIS (FR) | 2008-07-24 | — | — | US | disclosed |
| US-7371770-B2 | Acylaminothiazole derivatives and use thereof as β-amyloid inhibitors | SANOFIAVENTIS (FR) | 2008-05-13 | — | — | US | disclosed |
| US-20080076814-A1 | Hexahydro-Cyclooctyl Pyrazole Cannabinoid Modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-27 | — | — | US | disclosed |
| US-20050228034-A1 | Tetrahydro-indazole cannabinoid modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-10-13 | — | — | US | disclosed |
| CN-1055679-C | Phenethylamine derivative with cardiovascular activity | UNIV CHINA PHARMACY (CN) | 2000-08-23 | — | — | CN | disclosed |
| CN-1156141-A | Phenethylamine derivative with cardiovascular activity | UNIV CHINA PHARMACY (CN) | 1997-08-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176911-A1 | ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS | APP, BACE1, ATG4A | CNR2 4210/4885ALDH1A1 4081/4885KDM4E 1544/4885 |
| US-20050228034-A1 | Tetrahydro-indazole cannabinoid modulators | CNR2, CNR1, GPR18 | CNR2 1/4885ALDH1A1 1597/4885KDM4E 1714/4885 |
| US-20110230478-A1 | 4-Alkyl-substituted diaminopyrimidines | DPM1, DPYD, POLR1C | CNR2 4279/4885ALDH1A1 765/4885KDM4E 1081/4885 |
| US-11524961-B2 | JAK kinase inhibitor and preparation method and use thereof | JAK1, JAK2, JAK3 | CNR2 3458/4885ALDH1A1 3221/4885KDM4E 1409/4885 |
| US-20080076814-A1 | Hexahydro-Cyclooctyl Pyrazole Cannabinoid Modulators | CNR1, CNR2, FAAH | CNR2 2/4885ALDH1A1 2936/4885KDM4E 2159/4885 |
| US-20090099143-A1 | TETRAHYDRO-INDAZOLE CANNABINOID MODULATORS | CNR2, CNR1, GPR18 | CNR2 1/4885ALDH1A1 1597/4885KDM4E 1714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.